The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Evaluating the real-world safety and efficacy of BCMA-directed CAR-T in systemic AL amyloidosis
Matthew Rees, MD, St. Vincent’s Hospital, Melbourne, Australia, provides insight into a multicenter retrospective study that assessed the safety and efficacy of BCMA-directed CAR T-cell therapy in patients with systemic light chain (AL) amyloidosis and concurrent multiple myeloma (MM). Dr Rees confirms the feasibility of administering CAR-T in this patient population, as rates of cytokine release syndrome (CRS) were modest, and only isolated severe cases of CRS and immune cell-associated neurotoxicity syndrome (ICANS) were observed. He also notes that the majority of patients achieved a deep hematological response, which translated into organ improvement among evaluable patients. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
